Maria Luisa Alamillo

Mrs. Maria Luisa Alamillo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
JMJosé Ignacio Martínez-Montoro
José Ignacio Martínez-Montoro
JSJosé Juan Aparicio Sánchez
José Juan Aparicio Sánchez
BPBelén Belén Pimentel Pimentel
Belén Belén Pimentel Pimentel
MJMónica Juárez-Campo
Mónica Juárez-Campo
MAMaria Luisa Alamillo
Maria Luisa Alamillo
JFJose C. Fernandez-Garcia
Jose C. Fernandez-Garcia
To describe and characterize chronic kidney disease (CKD) prevalence, screening practices and associated burden on people with type 2 diabetes (T2D) managed by endocrinologists. Observational study, using secondary data from electronic health records (EHRs) (Telotron® database), with cross-sectional analysis at index date 30th November 2023. The study population included people with T2D who had at least one visit with an endocrinologist at the time of or after T2D diagnosis. CKD was defined by CKD diagnosis code or one estimated glomerular filtration rate (eGFR) value < 60 ml/min/1.73 m2 or one urine albumin-to-creatinine ratio (UACR) value ≥ 30 mg/g. Among 19,709 individuals with T2D, CKD prevalence was 40.7%, yet 54% of patients with CKD did not have a CKD diagnosis code. 56.5% of the T2D population did not have any registered UACR value in the year prior to the index date. People with T2D and CKD presented high prevalence of hypertension, hyperlipidemia, and heart failure, and high rates of medication use. CKD was highly prevalent in people with T2D managed by endocrinologists. Despite the high presence of comorbidities and medication use, we observed an important lack of screening and proper CKD identification.

21 August 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
JMJosé Ignacio Martínez-Montoro
José Ignacio Martínez-Montoro
JSJosé Juan Aparicio Sánchez
José Juan Aparicio Sánchez
BPBelén Belén Pimentel Pimentel
Belén Belén Pimentel Pimentel
MJMónica Juárez-Campo
Mónica Juárez-Campo
MAMaria Luisa Alamillo
Maria Luisa Alamillo
JFJose C. Fernandez-Garcia
Jose C. Fernandez-Garcia
Background/Objectives: Type 2 diabetes (T2D) is a major risk factor for cardiovascular disease and chronic kidney disease (CKD), yet the extent of longitudinal CKD screening in routine clinical practice remains unclear. This study aimed to assess long-term cardiorenal outcomes and CKD screening practices in patients with T2D managed across primary care and endocrinology settings, evaluating the feasibility of risk stratification in real-world practice. Methods: We conducted a retrospective cohort study using anonymized data from the Telotrón database (2.2 million patients). Adults with T2D attended across primary and endocrinology care were followed from 1 January 2018 to 31 December 2022. Frequency of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) measurements, and cumulative proportion of kidney and cardiovascular events, hospitalizations, and mortality were assessed. Results: Among 13,600 individuals, 31.1% experienced a kidney event and 18.6% a cardiovascular event over 5 years. All-cause hospitalization occurred in 24.9% and 16.1% died. First occurrence of an abnormal eGFR or UACR measurement occurred in 37.0% of participants without baseline CKD, and 45.4% with baseline CKD showed progression. Annual monitoring was limited, with 39.1% and 16.6% undergoing at least one yearly assessment, and 2.9 and 1.5 mean number of measurements per patient for eGFR and UACR, respectively. Conclusions: Despite receiving endocrinology care, kidney disease progression and cardiovascular events remain a major concern in T2D, and yet suboptimal albuminuria and eGFR assessment limit early detection and risk stratification, thereby hindering risk-directed management.